CA2925567C - Utilisation de l'odiparcil dans le traitement d'une mucopolysaccharidose - Google Patents

Utilisation de l'odiparcil dans le traitement d'une mucopolysaccharidose Download PDF

Info

Publication number
CA2925567C
CA2925567C CA2925567A CA2925567A CA2925567C CA 2925567 C CA2925567 C CA 2925567C CA 2925567 A CA2925567 A CA 2925567A CA 2925567 A CA2925567 A CA 2925567A CA 2925567 C CA2925567 C CA 2925567C
Authority
CA
Canada
Prior art keywords
odiparcil
mucopolysaccharidosis
treatment
use according
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2925567A
Other languages
English (en)
French (fr)
Other versions
CA2925567A1 (fr
Inventor
Philippe Masson
Jean-Louis Junien
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inventiva SA
Original Assignee
Inventiva SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inventiva SA filed Critical Inventiva SA
Publication of CA2925567A1 publication Critical patent/CA2925567A1/fr
Application granted granted Critical
Publication of CA2925567C publication Critical patent/CA2925567C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CA2925567A 2013-10-04 2014-10-03 Utilisation de l'odiparcil dans le traitement d'une mucopolysaccharidose Active CA2925567C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1359657 2013-10-04
FR1359657A FR3011468B1 (fr) 2013-10-04 2013-10-04 Utilisation de l'odiparcil dans le traitement d'une mucopolysaccharidose
PCT/FR2014/052507 WO2015049471A1 (fr) 2013-10-04 2014-10-03 Utilisation de l'odiparcil dans le traitement d'une mucopolysaccharidose

Publications (2)

Publication Number Publication Date
CA2925567A1 CA2925567A1 (fr) 2015-04-09
CA2925567C true CA2925567C (fr) 2021-10-05

Family

ID=49876835

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2925567A Active CA2925567C (fr) 2013-10-04 2014-10-03 Utilisation de l'odiparcil dans le traitement d'une mucopolysaccharidose

Country Status (28)

Country Link
US (1) US9561246B2 (ja)
EP (2) EP3047851B1 (ja)
JP (2) JP6412927B2 (ja)
KR (2) KR102345244B1 (ja)
CN (2) CN105636597B (ja)
AU (1) AU2014330977B2 (ja)
BR (1) BR112016007306B1 (ja)
CA (1) CA2925567C (ja)
CY (2) CY1117740T1 (ja)
DK (2) DK2857023T5 (ja)
EA (1) EA029370B1 (ja)
ES (2) ES2633806T3 (ja)
FR (1) FR3011468B1 (ja)
HK (1) HK1209033A1 (ja)
HR (2) HRP20160811T1 (ja)
HU (2) HUE027787T2 (ja)
IL (1) IL244829A0 (ja)
MA (1) MA38931B1 (ja)
MX (1) MX362596B (ja)
MY (1) MY184721A (ja)
PH (1) PH12016500541A1 (ja)
PL (2) PL3047851T3 (ja)
PT (2) PT2857023T (ja)
RS (2) RS54907B1 (ja)
SI (2) SI3047851T1 (ja)
TN (1) TN2016000111A1 (ja)
UA (1) UA117934C2 (ja)
WO (1) WO2015049471A1 (ja)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9982288B2 (en) * 2014-04-30 2018-05-29 The Nemours Foundation Mucopolysaccharidosis IVA/VII screening and treatment method

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0421829T3 (da) * 1989-09-22 1995-01-16 Fournier Ind & Sante Nye benzopyranon-beta-D-thioxylosider, fremgangsmåde til deres fremstilling og deres terapeutiske anvendelse
US6866844B2 (en) * 2002-11-07 2005-03-15 Biomarin Pharmaceutical Inc. Precursor N-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme
GB0400812D0 (en) * 2004-01-14 2004-02-18 Celltech R&D Ltd Novel compounds
EP2363129A1 (en) * 2004-10-13 2011-09-07 PTC Therapeutics, Inc. Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseases
FR2903698B1 (fr) * 2006-07-13 2009-01-30 Fournier S A Sa Lab Nouveaux derives de 5-thioxylopyranose.
WO2011163652A2 (en) * 2010-06-25 2011-12-29 Shire Human Genetic Therapies, Inc. Treatment of sanfilippo syndrome type b

Also Published As

Publication number Publication date
JP2016531888A (ja) 2016-10-13
CY1119212T1 (el) 2018-02-14
JP6545334B2 (ja) 2019-07-17
HK1209033A1 (zh) 2016-06-30
RS54907B1 (sr) 2016-10-31
EP2857023A1 (fr) 2015-04-08
HRP20160811T1 (hr) 2016-09-23
IL244829A0 (en) 2016-05-31
WO2015049471A1 (fr) 2015-04-09
ES2633806T3 (es) 2017-09-25
PL2857023T3 (pl) 2016-09-30
UA117934C2 (uk) 2018-10-25
US9561246B2 (en) 2017-02-07
ES2578161T3 (es) 2016-07-21
EP3047851B1 (fr) 2017-06-14
PT2857023T (pt) 2016-07-11
US20150099789A1 (en) 2015-04-09
EA201690709A1 (ru) 2016-07-29
JP2018162330A (ja) 2018-10-18
DK2857023T3 (en) 2016-07-25
RS56235B1 (sr) 2017-11-30
HUE027787T2 (en) 2016-10-28
PH12016500541A1 (en) 2016-06-13
EP2857023B1 (fr) 2016-04-20
BR112016007306A2 (pt) 2017-09-12
MY184721A (en) 2021-04-19
BR112016007306B1 (pt) 2022-09-06
CN109999049A (zh) 2019-07-12
MA38931B1 (fr) 2018-09-28
DK3047851T3 (en) 2017-09-18
MX2016004333A (es) 2016-11-10
TN2016000111A1 (fr) 2017-07-05
PL3047851T3 (pl) 2017-10-31
CA2925567A1 (fr) 2015-04-09
AU2014330977B2 (en) 2019-10-03
MA38931A1 (fr) 2018-04-30
KR102345244B1 (ko) 2021-12-30
KR20160058119A (ko) 2016-05-24
DK2857023T5 (en) 2016-08-29
FR3011468A1 (fr) 2015-04-10
CY1117740T1 (el) 2017-05-17
CN105636597A (zh) 2016-06-01
PT3047851T (pt) 2017-07-20
KR102328103B1 (ko) 2021-11-17
CN105636597B (zh) 2019-02-15
EP3047851A1 (fr) 2016-07-27
JP6412927B2 (ja) 2018-10-24
SI2857023T1 (sl) 2016-08-31
HRP20171305T1 (hr) 2017-10-20
FR3011468B1 (fr) 2015-12-04
SI3047851T1 (sl) 2017-10-30
EA029370B1 (ru) 2018-03-30
KR20210119562A (ko) 2021-10-05
MX362596B (es) 2019-01-25
HUE036306T2 (hu) 2018-06-28
CN109999049B (zh) 2022-01-25
AU2014330977A1 (en) 2016-05-19

Similar Documents

Publication Publication Date Title
NO329035B1 (no) Anvendelse av N-butyldeoksynojirimycin ved fremstilling av et medikament for behandling av en glykolipid-degraderingsforstyrrelse.
KR100969634B1 (ko) 글루코사민 또는 글루코사민 유도체를 포함하는 아토피성피부염 치료용 조성물 및 이를 사용하여 아토피성 피부염을치료하는 방법
JP4808619B2 (ja) 高血糖症の治療もしくは予防、または血糖の安定化に用いられる酵母細胞壁
CA2925567C (fr) Utilisation de l'odiparcil dans le traitement d'une mucopolysaccharidose
EP2528595A1 (de) Verbindungen zur verwendung bei der behandlung von erkrankungen
US10092540B2 (en) Method of treatment of a mucopolysaccharidosis
EP1100482B1 (fr) Utilisation des calix(n)arenes pour la fabrication d'un medicament pour le traitement des maladies fibrotiques
JPH04230628A (ja) 脂質調節薬としての10員環ラクトンの使用
WO1998009628A1 (en) Methods for inhibiting cardiac fibroblast growth and cardiac fibrosis
US20230277485A1 (en) Methods for the treatment of lysosomal storage diseases
CN115381818A (zh) 一种促进细胞自噬降解功能的方法及应用
BE886568A (fr) Composition pharmaceutique pour le traitement des affections degeneratives du cartilage articulaire, et methode d'utilisation de celle-ci.
Ghosh et al. Cartilage derived peptacans: novel nutraceuticals with immunomodulatory, anti-inflammatory and anti-arthritic activities.
JP2003174857A (ja) 食品組成物
FR2496462A1 (fr) Composition pharmaceutique a base de (+)-catechine, utile notamment pour le traitement des affections degeneratives du cartilage articulaire